You are here

Головна » Scientific Journal of Veterinary Medicine 2'2021

Determination of the drug Fagomast effectiveness with different titers of Phage SAvB14

Treatment of bacterial infections with bacteriophages is one of the alternative methods. However, the use of freely dispersed bacteriophages for treatment causes their inactivation under physiological conditions. Therefore, it is important to consider the concentration of bacteriophages in phage therapy. The aim of study – to determine the optimal titer of bacteriophage Phage SAvB14 in the drug Fagomast for the effective treatment of subclinical mastitis in cows caused by Stapholococcus aureus var. bovis. For research to determine the optimal therapeutic dose of the bacteriophage drug Fagomast in vitro, groups of animals were formed on the principle of analogues. Controls were animals treated with an antibiotic-based drug according to the instructions for use. Cows of the first experimental group were used samples of the drug with a titer of Phage SAvB14 10-7 BFU/ml, the second experimental group with a titer of 10-8 BFU/ml and the third group – 10-9 BFU/ml. It was found that all batches of Fagomast (81.8 - 92.8%) show good therapeutic efficacy, but the duration of treatment of animals was different. When using the drug Fagomast with a phage titer of 10-9 BFU/ml, it is shorter by 1 day than cows that were injected with a phage titer of 10-8 BFU/ml and 1.5 days compared with cows of the first group, which were injected with a phage titer of 10-7 BFU/ml. The results of the therapeutic efficacy of Fagomast with a bacteriophage titer of 10-8 and 10-9 BFU/ml in the drug are confirmed by the reaction with Mastidine, which after 48 hours was assessed as doubtful, and after 72 hours – as negative, as with antibiotic treatment. The content of S. aureus in the secretion of cows 12 hours after administration of the drug with a phage titer of 10-9 BFU/ml decreased 6 times (P ≤ 0.05), and after 48 hours 40 times (P ≤ 0.05), and after 60 hours of therapy did not stand out at all. The titer of bacteriophages remained at the level of 10-7 BFU/ml, and when the number of susceptible bacteria decreased to zero it decreased by 2 orders of magnitude. Thus, it can be said that maintaining a higher concentration of phage virions leads to better distribution of phages in the breast, and thus to improved binding of phages to host cells and their destruction.

Key words: bacteriophages, Staphylococcus aureus, phagotherapy, bacteriophage drug, mastitis, cows.

HORYUK Yu. https://orcid.org/0000-0002-7162-8992


  1. Fabijan, A. P., Lin, R. C., Ho, J., Maddocks, S., Zakour, N. L. B., Iredell, J. R. (2020). Safety of bacteriophage therapy in severe Staphylococcus aureus infection. Nature microbiology. Vol. 5, no. 3, pp. 465–472. DOI:10.1038/s41564-019-0634-z
  2. Manoharadas, S., Altaf, M., Alrefaei, A. F., Devasia, R. M., Hadj, A. Y. M. B., Abuhasil, M. S. A. (2021). Concerted dispersion of Staphylococcus aureus biofilm by bacteriophage and ‘green synthesized’silver nanoparticles. RSC Advances. Vol. 11, no. 3, pp. 1420–1429. DOI:10.1039/D0RA09725J
  3. Kim, S. G., Kwon, J., Giri, S. S., Yun, S., Kim, H. J., Kim, S. W., Park, S. C. (2021). Strategy for mass production of lytic Staphylococcus aureus bacteriophage pSa-3: contribution of multiplicity of infection and response surface methodology. Microbial Cell Factories. Vol. 20, no. 1, pp. 1–12. DOI:10.1186/s12934-021-01549-8
  4. Horiuk, Y. V. (2019). Lytic Activity of Staphylococcal Bacteriophage on Different Biotypes of Staphylococcus aureus. Scientific Messenger of LNU of Veterinary Medicine and Biotechnologies. Series: Veterinary Sciences. Vol. 21, no. 94, pp. 115–120. DOI:10.32718/nvlvet9421
  5. Kakasis, A., Panitsa, G. (2019). Bacteriophage therapy as an alternative treatment for human infections. A comprehensive review. International journal of antimicrobial agents. Vol. 53, no. 1, pp. 16–21. DOI:10.1016/j.ijantimicag.2018. 09.004
  6. Prasuhn Jr, D. E., Singh, P., Strable, E., Brown, S., Manchester, M., Finn, M. G. (2008). Plasma clearance of bacteriophage Qβ particles as a function of surface charge. Journal of the American Chemical Society. Vol. 130, no. 4, pp. 1328–1334. DOI:10.1021/ja075937f
  7. Luong, T., Salabarria, A. C., Edwards, R. A., Roach, D. R. (2020). Standardized bacteriophage purification for personalized phage therapy. Nature Protocols. Vol. 15, no. 9, pp. 2867–2890. DOI:10.1038/s41596-020-0346-0
  8. Bonilla, N., Rojas, M. I., Cruz, G. N. F., Hung, S. H., Rohwer, F., Barr, J. J. (2016). Phage on tap-a quick and efficient protocol for the preparation of bacteriophage laboratory stocks. Peer J. Vol. 4, pp. 1–18. DOI:10.7717/peerj.2261
  9. Payne, R. J., Jansen, V. A. (2000). Phage therapy: the peculiar kinetics of self‐replicating pharmaceuticals. Clinical pharmacology & therapeutics. Vol. 68, no. 3, pp. 225–230. DOI:10.1067/mcp.2000.109520
  10. Srujana, A. S., Sonalika, J., Akhila, D. S., Juliet, M. R., Sheela, P. (2021). Isolation of Phages and Study of their In vitro Efficacy on Staphylococcus aureus Isolates Originating from Bovine Subclinical Mastitis. Indian Journal of Animal Research. Vol. 1, pp. 1–5. DOI:10.18805/IJAR.B-4331
  11. Abedon, S. (2011). Phage therapy pharmacology: calculating phage dosing. Advances in applied microbiology. Vol. 77, pp. 1–40. DOI: 10.1016/B978-0-12-387044-5.00001-7
  12. Nilsson, A. S. (2019). Pharmacological limitations of phage therapy. Upsala journal of medical sciences. Vol. 124, no. 4, pp. 218–227. DOI: 10.1080/03009734.2019.1688433
  13. Manohar, P., Tamhankar, A. J., Leptihn, S., Ramesh, N. (2019). Pharmacological and immunological aspects of phage therapy. Infectious Microbes & Diseases. Vol. 1, no. 2, pp. 34–42. DOI:10.1097/IM9.0000000000000013
  14. Song, J., Ruan, H., Chen, L., Jin, Y., Zheng, J., Wu, R., Sun, D. (2021). Potential of bacteriophages as disinfectants to control of Staphylococcus aureus biofilms. BMC microbiology. Vol. 21, no. 1, pp. 1–14. DOI:10.1186/s12866-021-02117-1
  15. Horiuk, Y. V., Kukhtyn, M. D., Stravskyy, Y. S., Klymnyuk, S. I., Vergeles, K. M., Horiuk, V. V. (2019). Influence of staphylococcal Phage SAvB14 on biofilms, formed by Staphylococcus aureus variant bovis. Regulatory Mechanisms in Biosystems. Vol. 10, no. 3, pp. 314– 318. DOI:10.15421/021948
  16. Danis-Wlodarczyk, K., Dąbrowska, K., Abedon, S. T. (2020). Phage therapy: the pharmacology of antibacterial viruses. Current Issues in Molecular Biology. Vol. 40, no. 1, pp. 81–164. DOI:10.21775/cimb.040.081
  17. Hoyland-Kroghsbo, N. M., Mærkedahl, R. B., Svenningsen, S. L. (2013). A quorum-sensing-induced bacteriophage defense mechanism. MBio, Vol. 4, no. 1, pp. 1–8. DOI:10.1128/mBio.00362-12
  18. Horiuk, Y. (2020). The effect of various titers of bacteriophages on the amount of Staphylococcus aureus variant bovis. Veterinary Science, Technologies of Animal Husbandry and Nature Management. Vol. 5, pp. 26–31. DOI:10.31890/vttp.2020.05.05
  19. Krömker, V., Zinke, C., Paduch, J. H., Klocke, D., Reimann, A., Eller, G. (2010). Evaluation of increased milking frequency as an additional treatment for cows with clinical mastitis. Journal of dairy research. Vol. 77, no. 1, pp. 90–94. DOI: 10.1017/S0022029909990422
  20. O'flaherty, S., Coffey, A., Meaney, W., Fitzgerald, G. F., Ross, R. P. (2005). The recombinant phage lysine LysK has a broad spectrum of lytic activity against clinically relevant staphylococci, including methicillin-resistant Staphylococcus aureus. Journal of bacteriology. Vol. 187, no. 20, pp. 7161– 7164. DOI:10.1128/JB.187.20.7161-7164.2005
  21. Titze, I., Lehnherr, T., Lehnherr, H., Krömker, V. (2020). Efficacy of bacteriophages against Staphylococcus aureus isolates from bovine mastitis. Pharmaceuticals. Vol. 13, no. 3, pp. 1–22. DOI:10.3390/ph13030035
  22. Gill, J. J., Pacan, J. C., Carson, M. E., Leslie, K. E., Griffiths, M. W., Sabour, P. M. (2006). Efficacy and pharmacokinetics of bacteriophage therapy in treatment of subclinical Staphylococcus aureus mastitis in lactating dairy cattle. Antimicrobial agents and chemotherapy. Vol. 50, no. 9, pp. 2912–2918. DOI: 10.1128/AAC.01630-05
  23. Iwano, H., Inoue, Y., Takasago, T., Kobayashi, H., Furusawa, T., Taniguchi, K., Tamura, Y. (2018). Bacteriophage ΦSA012 has a broad host range against Staphylococcus aureus and effective lytic capacity in a mouse mastitis model. Biology. Vol. 7, no. 1, pp. 1–13. DOI:10.3390/biology7010008
  24. Kraushaar, B., Thanh, M. D., Hammerl, J. A., Reetz, J., Fetsch, A., Hertwig, S. (2013). Isolation and characterization of phages with lytic activity against methicillin-resistant Staphylococcus aureus strains belonging to clonal complex 398. Archives of virology. Vol. 158, no. 11, pp. 2341–2350. DOI:10.1007/s00705-013-1707-6
  25. Geng, H., Zou, W., Zhang, M., Xu, L., Liu, F., Li, X., Xu, Y. (2020). Evaluation of phage therapy in the treatment of Staphylococcus aureus-induced mastitis in mice. Folia microbiologica. Vol. 65, no. 2, pp. 339–351. DOI: 10.1007/s12223-019-00729-9
  26. Wills, Q. F., Kerrigan, C., Soothill, J. S. (2005). Experimental bacteriophage protection against Staphylococcus aureus abscesses in a rabbit model. Antimicrobial agents and chemotherapy. Vol. 49, no. 3, pp. 1220–1221. DOI: 10.1128/AAC.49.3.1220-1221.2005
AttachmentSize
PDF icon horiuk_2_2021.pdf495.66 KB
Scientific Journal of Veterinary Medicine 2'2021